Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block
Status:
Withdrawn
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The goals of this study are as follows:
1. to confirm the safe dosing of ropivacaine for the erector spinae plane block
2. develop a pharmacokinetic profile of the erector spinae plane block, which will help
demonstrate how quickly and how closely toxic levels are reached when a routine dose of
ropivacaine is given for this nerve block
3. assess numbness created by the erector spinae block when routine doses are administered